RxDoctor Payments Data

Alicia Cole, MD

Internal Medicine · Charlotte, NCNPI 1376562728

Payments from drug & device makers

$1,520in general payments, 2019–2025

Across 83 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$327
  • GSK$280
  • Novo Nordisk$230
  • Pfizer$178
  • Abbott$153
  • Amgen$81
  • plus $272 from 11 others

What the payments were for

  • Food & beverage$1,48998%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,520 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$142,053
Medicare patients
384
Services billed
2,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$134,502
EliquisApixaban82$83,347
FarxigaDapagliflozin Propanediol89$72,440
XareltoRivaroxaban55$50,433
MounjaroTirzepatide37$39,499
RybelsusSemaglutide33$35,417
JardianceEmpagliflozin22$33,515
TrulicityDulaglutide23$25,793
Tresiba Flextouch U-100Insulin Degludec30$16,400
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,738
Xultophy 100-3.6Insulin Degludec/Liraglutide11$14,021
SynthroidLevothyroxine Sodium109$9,444
Rosuvastatin Calcium736$7,345
MyrbetriqMirabegron13$7,118
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$5,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$230$183,940148 claims
PfizerEliquis$178$83,34782 claims
AstraZenecaFarxiga$38$72,44089 claims
Lilly USA, LLCMounjaro, Trulicity$13$65,29260 claims
Boehringer IngelheimJardiance$12$33,51522 claims
GSKTrelegy Ellipta$280$14,73819 claims
AbbVieSynthroid$327$9,444109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →